D-DIMER AS A BIOMARKER FOR DISEASE SEVERITY IN COVID-19 PATIENTS: SOME PHYSIOLOGICAL ASPECTS
DOI:
https://doi.org/10.52340/jecm.2023.01.09Keywords:
D-dimer, COVID–19, bloodAbstract
Because of the rapid spreading and high mortality of Covid-19, it represents a global problem. According to the literature, an increase in the level of D-dimer was indicated during complications of disease and mortality. To the above-mentioned, we studied the D-dimer level in patients with Covid-19. In total, we investigated 40 Covid infected patients. As research material, we used blood. The research results showed that the level of D-dimer increases significantly in Covid-19 infected patients. And, its increasing level is associated with the severity of patients (p<0,0001). In particular, a high level of D-dimer was shown in the patients that died in the hospital. Therefore D-dimer could be used as a biomarker during Covid disease in Covid-19 patients and for prognosis and treatment management in clinical practice.
Downloads
References
Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine, 382(18):1708-20.
Wong, J. P., Viswanathan, S., Wang, M., et al. (2017). Current and future developments in the treatment of virus-induced hypercytokinemia. Future medicinal chemistry, 9(2):169–178.
Tang, N., Bai, H., Chen, X., Gong, J., Li, D., Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and hemostasis: JTH, 18(5):1094–1099.
Wichmann, D., Sperhake, J. P., Lütgehetmann, M., Steurer, S., Edler, C., Heinemann, A., Kluge, S. (2020). Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Annals of internal medicine, 173(4):268-277.
Zhang, J. J., Dong, X., Cao, Y. Y., Yuan, Y. D., Yang, Y. B., Yan, Y. Q., Gao, Y. D. (2020). Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy, 75(7):1730-1741.